Author

Lorna Morris

Berlin Institute of Health at Charité - Universitätsmedizin BerlinORCID 0000-0002-3441-803XUnclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Genomics· 1 Systems Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Research Focus:gene regulatory network inference· 1 Organism:human· 1 Assay:long-read sequencing· 1 Organism:mouse· 1

Frequent Co-Authors

Agata RakszewskaiD· 1 shared Alexander E KeliD· 1 shared Barry James CampbelliD· 1 shared Carrie A. DuckworthiD· 1 shared Chris Probert· 1 shared Christian ConradiD· 1 shared David G. SpilleriD· 1 shared David Mark PritchardiD· 1 shared

Activity by Year

2020-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperGenomics

Agata RakszewskaORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Long-read single-cell RNA sequencing uncovers cell-type specific transcript regulation in COVID-19

Kristin Köhler, Lorna Morris, Agata Rakszewska, Robert Lorenz Chua, Maciej Balura, Katharina Jechow, Jennifer Loske, Roland Eils, Irina Lehmann, Peter N. Robinson, Christian Conrad

This study uses long-read single-cell RNA sequencing to identify cell-type specific alternative splicing changes in COVID-19 patients compared to healthy controls.

bioRxiv · Sep 23, 2025 · PreprintGenomics

Identification of a novel therapeutic agent for Inflammatory Bowel Disease guided by systems medicine

Katie Lloyd, Stamatia Papoutsopoulou, Emily Smith, Philip Stegmaier, François Bergey, Lorna Morris, Madeleine Kittner, Hazel England, David G. Spiller, Michael White, Carrie A. Duckworth, Barry James Campbell, Vladimir Poroikov, Vítor A. P. Martins dos Santos, Alexander E Kel, , Michael David Burkitt

This study identifies clarithromycin as a potential therapeutic for inflammatory bowel disease through in-silico drug repositioning and experimental validation of its effects on NF-κB signaling.

Disease Models & Mechanisms · Sep 21, 2020Peer-reviewedSystems Biology